Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

NCT ID: NCT00195156

Last Updated: 2006-09-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-07-31

Brief Summary

The purpose of this study is to find out the highest tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.

Detailed Description

To determine the maximum tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.

This will be a 2-step dose escalation study. Once the patient starts therapy at a designated dose level, it will not be escalated for that patient. Three patients at each dose level must complete 4 weeks of therapy before escalating to the next higher level. If none of the patients experience dose limiting toxicity (DLT), then 3 new patients will be treated with the next higher dose level.

Conditions

Solid Tumor Malignancies

Keywords

Solid Tumor Malignancies

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

ATRA-IV

Intervention Type: DRUG

Depakote

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with histologic confirmation of a solid tumor malignancy with clinical evidence of metastatic disease.
• Patients must have failed at least one standard therapy, if available, for their malignancy. Patients may be entered on the trial without prior therapy if there is no standard effective therapy available.
• No active brain metastases or epidural tumor.

Exclusion Criteria

• Concomitant administration of steroids.
• Irradiation or chemotherapy within 14 days of start of protocol.
• Evidence of another active cancer, except for non-melanoma, carcinoma of the skin and in-situ carcinoma of the cervix curatively treated, Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for greater than 5 years.
• Women who are pregnant or lactating. Women or men of reproductive age who are unwilling to use two forms of effective contraception.
• Patients with clinically significant cardiac, renal or hepatic disease; severe debilitating pulmonary disease; or history of diabetes mellitus prone to ketoacidosis.
• Patients with a history of pancreatitis.
• Patients with known hypersensitivity to retinoids or retinoic acid derivatives.
• Patients with coagulation disorders, such as thrombophlebitis or pulmonary embolism.
• Patients with pre-existing psychiatric condition, especially depression or a history of severe uncontrolled psychiatric disorder.
• Patients with pre-existing thyroid abnormalities whose thyroid function cannot be maintained in the normal range.
• Patients with chronic moderate to severe nausea.
• Patients with history of epilepsy or a seizure disorder taking anti-convulsant medication.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Weill Medical College of Cornell University

OTHER

Sponsor Role: lead

Principal Investigators

David Nanus, M.D.

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Weill Medical College of Cornell University

New York, New York, United States

Countries

United States

References

Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). Eur J Haematol. 2020 Mar;104(3):236-250. doi: 10.1111/ejh.13367. Epub 2020 Jan 13.

Reference Type: DERIVED

PMID: 31811682 (View on PubMed)

Other Identifiers

1002-536

Identifier Type: -

Identifier Source: org_study_id